| Budget impact analysis of insulin therapies and associated delivery systems. | |
| | |
MedLine Citation:
|
PMID: 22610028 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Purpose A budget impact analysis of insulin therapies and associated delivery systems is presented. Methods Based on inputted procurement totals, per-item costs (based on 2011 average wholesale price), insulin distribution system (floor stock or individual patient supply), waste, and treatment protocols for a specified time frame, the budget impact model approximated the number of patients treated with subcutaneous insulin, costs, utilization, waste, and injection mechanism (pen safety needle or syringe) costs. To calculate net changes, results of one-year 3-mL vial use were subtracted from one-year 10-mL vial or 3-mL pen use. Results Switching from a 10-mL vial to a 3-mL vial was associated with reductions in both costs and waste. The net reductions in costs and waste ranged from $15,482 and 120,000 IU, respectively, for floor-stock 10-mL vial to floor-stock 3-mL vial conversion to $871,548 and 6,750,000 IU, respectively, for individual patient supply 10-mL vial to floor-stock 3-mL vial conversion. Switching from floor-stock 10-mL vials to individual patient supply 3-mL vials increased costs and waste by $164,659 and 1,275,000 IU, respectively. Converting from individual patient supply 3-mL pens to individual patient supply 3-mL vials reduced costs by $117,236 but did not decrease waste. Conclusion A budget impact analysis of the conversion of either 10-mL insulin vials or 3-mL insulin pens to 3-mL insulin vials found reductions in both cost and waste, except when converting from floor-stock 10-mL vials to individual patient supply 3-mL vials. |
| | |
Authors:
|
Lauren J Lee; Lee J Smolen; Timothy M Klein; Shonda A Foster; Doug Whiteman; James A Jorgenson; Steve Hultgren |
Related Documents
:
|
1916668 - Screening for candidate hepatic growth factors by selective portal infusion after canin... 18411128 - Therapeutic potential of insulinlike growth factor i. 17192298 - The effect of growth hormone on the response of total and acylated ghrelin to a standar... 2149688 - Effects of octreotide on lipoproteins and endothelial function of type 1 (insulin-depen... 750488 - Hypoglycemic responses to insulin in normothermic and hyperthermic young dogs. 8331618 - Glucose metabolism during the menstrual cycle. assessment with the euglycemic, hyperins... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists Volume: 69 ISSN: 1535-2900 ISO Abbreviation: Am J Health Syst Pharm Publication Date: 2012 Jun |
Date Detail:
|
Created Date: 2012-05-21 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9503023 Medline TA: Am J Health Syst Pharm Country: United States |
Other Details:
|
Languages: eng Pagination: 958-65 Citation Subset: IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Performance of a vancomycin dosage regimen developed for obese patients.
Next Document: Analyzing methods for improved management of workflow in an outpatient pharmacy setting.